CMMB FY 2021 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$34,023

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-4.80

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$64M

Total Liabilities

$3M

Stockholders' Equity

$61M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$34,023	-$79,999	+57.5%
Operating Income	-$12M	-$6M	-107.1%
Net Income	-$12M	-$6M	-109.7%